FDA
-
-
-
-
-
-
-
CorMedix Announces Completion of Enrollment in Phase III ReSPECT Clinical Trial for REZZAYO
-
-
-
-
-
-
-
CorMedix to acquire Melinta Therapeutics for $300 million
-
-
-
-
-
-
-
Grabar Law Office Investigates Claims on Behalf of Shareholders of CorMedix Inc. (CRMD) as Securities Fraud Class Action Survives Motion to Dismiss
-
-
-
-
-
-
-
CorMedix (CRMD) Announces Customer Implementation
-
-
-
-
-
-
-
CorMedix (CRMD) Announces Preliminary First Quarter 2025 Results and Raises H1 2025 Net Sales Guidance
-
-
-
-
-
-
-
CorMedix Inc. Announces Preliminary Fourth Quarter 2024 Results and Provides Business Update
-
-
-
-
-
-
-
CorMedix Inc. to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on October 30, 2024
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

